spacer
home > epc > autumn 2008 > future functions
PUBLICATIONS
European Pharmaceutical Contractor

Future Functions

It is nearly 20 years since the first commercial imaging core laboratory was founded. Today, there are numerous commercial imaging core laboratories, numerous international imaging biomarker meetings and regulatory guidance documents to support the use of imaging in drug development. Many academic, government and commercial entities have contributed to the growth of this approach, which has become a mainstream tool for the development of numerous therapeutic drugs.

Medical imaging endpoints are accepted in many clinical trials, and when included in the study design, the FDA requires the implementation of a central, independent image review process. The proliferation of medical imaging endpoints and the resulting management, analysis and submission of medical imaging data has fostered the healthy growth of the medical imaging core lab industry, both for commercial and academic labs. The increase in the number of labs and studies for which they provide services led to a somewhat varied set of documentation and implementation of various technology methods for what is a largely consistent undertaking. Pharmaceutical trial sponsors and the FDA initiated the desire for standardisation in these trials, and DIA has provided the leadership needed to obtain collaboration from all affected parties.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
James Conklin is the Senior Vice President for medical and scientific affairs at ICON Medical Imaging. James is a John Hopkins-trained research physician with undergraduate and graduate training in electrical/computer engineering and a Masters degree in Management. He has been a Professor of Radiology at several medical schools, published over 100 scientific papers and edited four books. One of the textbooks, Imaging Techniques in Biology and Medicine, published by Academic Press in 1987, provided the technical foundation for Bio-Imaging Technologies, Inc. He is board certified in both internal medicine and nuclear medicine.
spacer
James Conklin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement